



PATENTS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant(s):** Jose Repolles Moliner, et al.

**Examiner:** D. Lukton

**Serial No:** 09/912,164

**Art Unit:** 1653

**Filed:** March 16, 2001

**Docket:** 14797

**For:** S-NITROSOTHIOLS AS AGENTS FOR  
THE TREATMENT OF CIRCULATORY  
DYSFUNCTIONS

**Dated:** July 30, 2003

Commissioner for Patents  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Giustarini, D. et al., "Nitric oxide and S-nitrosothiols in human blood", Clinica Chimica Acta, 330(1-2): 85-98 (2003);
2. Radomski, R. et al. "Systemic effects of S-nitroso-gluthione in the human following intravenous infusion", British Journal of Pharmacology, 40(1): 101-102 (1995);
3. de Belder, A. et al. "Effects of S-nitroso-glutathione in the human forearm circulations: evidence for selective inhibition of platelet activation", Cardiovascular Research, 28: 691-694 (1994);

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on July 30, 2003.

Dated: July 30, 2003

  
Mark J. Cohen

08/05/2003 ZJUH8R1 00000133 09912164

01 FC:1806

180.00 0P


4. Stamler, J. et al. "Endothelium-Derived Relaxing Factor Modulates the Atherothrombogenic Effects of Homocysteine", Journal of Cardiovascular Pharmacology, 20(12): 202-204 (1992);
5. Megson, I. et al. "Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells *in vitro*: implications for anti-thrombotic therapy", British Journal of Pharmacology, 131: 1391-1398 (2000);
6. Inbal, A. et al. "Unique Antiplatelet Effects of a Novel S-Nitrosoderivative of a Recombinant Fragment of von Willebrand Factor, AR545C: In Vitro and Ex Vivo Inhibition of Platelet Function", Blood, 94(5): 1693-1700 (1999);
7. United States Patent Application Publication No. 2002/0037839 A1, published March 28, 2002;
8. International Patent Application No. WO 98/42753, published October 1, 1998; and
9. International Patent Application No. WO 89/12627, published December 28, 1989.

Applicants are submitting copies of the above-cited references. All of the references are in English, therefore, no translations are required.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(c), the \$180.00 fee is enclosed.

Consideration of this Information Disclosure Statement is respectfully requested.

Respectfully submitted,

  
Mark J. Cohen  
Registration No. 32,211

Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, New York 11530

MJC:lf



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(REV. 7-80) PATENT AND TRADEMARK OFFICE

Atty. Docket No.  
14797

Serial N.  
09/912,164

# LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Jose Repolles Moliner, et al.

Filing Date  
March 16, 2001

Group  
1653

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA	2002/0037839	3/28/02	Stamler, et al.			
	AB						
	AC						
	AD						
	AE						

		Foreign Document Number	Date	Country	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 89/12627	12/28/89	PCT				
		WO 98/42753	10/1/98	PCT				

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		Giustarini, D. et al., "Nitric oxide and S-nitrosothiols in human blood", <u>Clinica Chimica Acta</u> , 330(1-2): 85-98 (2003)
		Radomski, R. et al. "Systemic effects of S-nitroso-gluthione in the human following intravenous infusion", <u>British Journal of Pharmacology</u> , 40(1): 101-102 (1995)
		de Belder, A. et al. "Effects of S-nitroso-glutathione in the human forearm circulations: evidence for selective inhibition of platelet activation", <u>Cardiovascular Research</u> , 28: 691-694 (1994)
		Stamler, J. et al. "Endothelium-Derived Relaxing Factor Modulates the Atherothrombotic Effects of Homocysteine", <u>Journal of Cardiovascular Pharmacology</u> , 20(12): 202-204 (1992)
		Megson, I. et al. "Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells <i>in vitro</i> : implications for anti-thrombotic therapy", <u>British Journal of Pharmacology</u> , 131: 1391-1398 (2000)
		Inbal, A. et al. "Unique Antiplatelet Effects of a Novel S-Nitrosoderivative of a Recombinant Fragment of von Willebrand Factor, AR545C: In Vitro and Ex Vivo Inhibition of Platelet Function", <u>Blood</u> , 94(5): 1693-1700 (1999)

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

16534

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))		Docket No. 14797	
In Re Application Of: Jose Repolles Moliner, et al.			
Serial No. 09/912,164	Filing Date March 16, 2001	Examiner D. Lukton	Group Art Unit 1653
Title: S-NITROSOTHIOLS AS AGENTS FOR THE TREATMENT OF CIRCULATORY DYSFUNCTIONS			
<p>Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> <p><b>37 CFR 1.97(b)</b></p> <p>1. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p><b>37 CFR 1.97(c)</b></p> <p>2. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p>OR</p> <p><input checked="" type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>			

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
14797

In Re Application: Jose Repolles Moliner, et al.

Serial No.  
09/912,164

Filing Date  
March 16, 2001

Examiner  
D. Lukton

Group Art Unit  
1653

**S-NITROSOTHIOLS AS AGENTS FOR THE TREATMENT OF CIRCULATORY DYSFUNCTIONS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☒ A check in the amount of **\$180.00** is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.
- ☐ Charge the amount of
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on **7/30/03** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Signature

Mark J. Cohen

Typed or Printed Name

*\*This certificate may only be used if paying by deposit account.*

Signature

Dated: July 30, 2003

Mark J. Cohen  
Registration No. 32,211  
Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, NY 11530  
(516) 742-4343

CC: